TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24448756
Drug: Aranesp (Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aranesp (Q weekly or Q 2 weeks)
Study: 18408527
Drug: Olanzapine treatment
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine treatment for psychotic depression
Study: 18408527
Drug: Cumulative olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cumulative olanzapine dose
Study: 1749203
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (atenolol and nifedipine)
Study: 6810863
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of SCG and theophylline
Study: 31349978
Drug: Intravenous Dodecafluoropentane
Normalized name: Dodecafluoropentane
DrugBank: Perflenapent (DB11625)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Dodecafluoropentane emulsion (DDFPe)
Study: 31349978
Drug: High-dose DDFPe
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose DDFPe
Study: 28324038
Drug: Exenatide plus
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide plus pioglitazone (combination therapy)
Study: 28324038
Drug: Basal plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal plus prandial insulin (insulin therapy)
Study: 21594619
Drug: Selumetinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selumetinib (100 mg oral twice daily)
Study: 21594619
Drug: Capecitabine (1,250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine (1,250 mg/m² oral twice daily)
Study: 19349375
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate infusion (3 doses of 250 mg/kg per dose, 1 mL/kg per dose, 24 hours apart)
Study: 19349375
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion (3 doses of 1 mL/kg per dose, 24 hours apart)
Study: 17224418
Drug: Active therapy
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active therapy (Pm ON)
Study: 17224418
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy (Pm OFF)
Study: 14684561
Drug: rhDNase (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhDNase (2.5 mg/day)
Study: 12162793
Drug: Desloratadine 5-20
Normalized name: desloratadine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine 5-20 mg
Study: 12162793
Drug: Desloratadine 5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine 5, 7.5, and 20 mg
Study: 12162793
Drug: Desloratadine 5
Normalized name: desloratadine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine 5 mg QD
Study: 9839823
Drug: bupivacaine 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 150 mg + morphine 4 mg
Study: 9839823
Drug: bupivacaine 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 150 mg + morphine 4 mg + methylprednisolone 40 mg
Study: 7666668
Drug: MFC +
Normalized name: Metformin Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFC + continuous oral 5-FU (Group A)
Study: 7666668
Drug: MFC +
Normalized name: Metformin Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFC + continuous oral UFT (Group B)
Study: 7666668
Drug: MFC +
Normalized name: Metformin Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFC + continuous oral 5-FU (Group A) at CAD
Study: 7666668
Drug: MFC +
Normalized name: Metformin Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFC + continuous oral UFT (Group B) at CAD
Study: 7666668
Drug: MFC +
Normalized name: Metformin Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFC + continuous oral 5-FU (Group A) at CIH
Study: 7666668
Drug: MFC +
Normalized name: Metformin Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFC + continuous oral UFT (Group B) at NCC
Study: 25559495
Drug: Multitiered oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multitiered oral health educational program for care staff
Study: 8665335
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (10‐30 mg four times a day)
Study: 2005708
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms desmopressin spray
Study: 6364441
Drug: Naloxone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (8 mg loading dose followed by 5.6 mg/h continuous infusion from midnight until 10 am)
Study: 27927048
Drug: BTDS 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTDS 10 mcg/h
Study: 27927048
Drug: BTDS 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTDS 40 mcg/h
Study: 27927048
Drug: BTDS 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTDS 80 mcg/h
Study: 25210019
Drug: Targeted albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Targeted albendazole therapy (n = 467)
Study: 25210019
Drug: Nontargeted albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nontargeted albendazole therapy (n = 513)
Study: 25210019
Drug: Albendazole therapy
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole therapy (both targeted and nontargeted)
Study: 23471702
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of amlodipine, telmisartan, and hydrochlorothiazide
Study: 9112303
Drug: Sit up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sit up and take 20 deep breaths on 10 occasions daily (group B)
Study: 9112303
Drug: Sit up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sit up and blow bubbles in a bottle containing 10 cm water through a plastic tube 20 times on 10 occasions daily (group C)
Study: 3322828
Drug: Digoxin marker
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin marker in capsules of gemfibrozil (4.4 micrograms twice a day)
Study: 3322828
Drug: Digoxin marker
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin marker in capsules of placebo (4.4 micrograms twice a day)
Study: 31537375
Drug: Dilute betadine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilute betadine (0.02% solution) added to sterile water (SW) splash basin
Study: 21575102
Drug: Dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 μg·kg(‐1)
Study: 21575102
Drug: Dexmedetomidine 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 2 μg·kg(‐1)
Study: 21575102
Drug: Fentanyl 2
Normalized name: fentanyl 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 2 μg·kg(‐1)
Study: 21575102
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (acetaminophen as needed)
Study: 18470742
Drug: Multiple channel
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple channel exposure therapy (M-CET)
Study: 16782927
Drug: Carboplatin and
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin and cisplatin (CC)
Study: 9926970
Drug: Pamidronate 60
Normalized name: pamidronate 60 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate 60 mg i.v. every 3 weeks for a maximum of six cycles
Study: 9926970
Drug: Pamidronate 90
Normalized name: pamidronate 90 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate 90 mg i.v. every 3 weeks for a maximum of six cycles
Study: 10843163
Drug: Pamidronate treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate treatment
Study: 10739358
Drug: Average monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Average monthly direct costs during treatment phase
Study: 10739358
Drug: Average monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Average monthly direct costs during follow-up
Study: 9176830
Drug: 1.25 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 g/day DHA
Study: 9176830
Drug: 2.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g/day DHA
Study: 1412606
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 200 mg of labetalol
Study: 1412606
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose of 0.5 mg/kg of labetalol
Study: 30861510
Drug: Vaginal suppositories
Normalized name: Miconazole Nitrate Vaginal Suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal suppositories containing low‐molecular‐weight hyaluronic acid (HA) from day 1 of radiotherapy for 5 weeks.
Study: 26972955
Drug: Diet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet therapy plus pravastatin
Study: 20942575
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (combination of antioxidants extracted from fruit, berries, and vegetables) for 12 weeks
Study: 10357412
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with monitoring using [technetium 99m]-sestamibi (MIBI) scintimammography
Study: 7497759
Drug: Normothermic CPB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normothermic CPB (n = 19, rectal temperature: 35.9 ± 0.1 degrees C)
Study: 7497759
Drug: Hypothermic CPB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermic CPB (n = 19, rectal temperature: 29.2 ± 0.5 degrees C)
Study: 2149508
Drug: Goserelin (Zoladex)
Normalized name: goserelin Drug Implant [Zoladex]
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Goserelin (Zoladex) 3.6 mg depot preparation combined with flutamide (Eulexin) 250 mg t.i.d.
Study: 6997516
Drug: Seven-day regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven-day regimen of metronidazole (250 mg three times daily)
Study: 22126349
Drug: Fluoride chewing
Normalized name: sodium fluoride Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride chewing gum (FCG: 50 μg fluoride)
Study: 18174269
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 1.2 g/day for 2 days
Study: 18174269
Drug: Zinc (Zn)
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc (Zn) 60 mg/day for 1 day
Study: 17023703
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein with native phytate (40 g/d)
Study: 9822499
Drug: Daily aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily aspirin (60 mg)
Study: 2698360
Drug: Trabeculectomy at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy at diagnosis followed by supplementary medical therapy if necessary
Study: 2698360
Drug: Conventional management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional management of medical therapy followed by trabeculectomy in unsuccessful cases
Study: 4876730
Drug: Therapeutic trial
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic trial treatment
Study: 4876730
Drug: Earlier trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Earlier trial treatment in Morocco
Study: 31369613
Drug: Motor control
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motor control (low‐dose exercise) and manual therapy
Study: 31369613
Drug: General strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: General strength and conditioning training (moderate‐dose exercise)
Study: 17786128
Drug: TDM-directed dose
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDM-directed dose modifications
Study: 14681839
Drug: Copper supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copper supplementation (3 mg copper/d as copper-glycinate) for 6 weeks
Study: 14681839
Drug: Copper supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copper supplementation (3 mg copper/d as copper-glycinate) plus zinc supplementation (30 mg zinc/d as zinc-glycinate) for 6 weeks
Study: 9449404
Drug: Potassium 40
Normalized name: penicillin G potassium 400000 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium 40 mmol, Calcium 30 mmol (1200 mg), Magnesium 14 mmol (336 mg)
Study: 9449404
Drug: Calcium 30
Normalized name: CALCIUM 300MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 30 mmol (1200 mg)
Study: 9449404
Drug: Magnesium 14
Normalized name: Calcium/Gelatin/Magnesium 144 MG-324 MG-140 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium 14 mmol (336 mg)
Study: 7616978
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate (1.9 mg/mL) plus droperidol (0.125 mg/mL)
Study: 7616978
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate (2 mg/mL)
Study: 2374275
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid (1.5 g three times daily)
Study: 31409606
Drug: vonoprazan 20
Normalized name: vonoprazan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: vonoprazan 20 mg once daily for 8 weeks
Study: 31409606
Drug: vonoprazan 20
Normalized name: vonoprazan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: vonoprazan 20 mg once daily for 2 weeks
Study: 31409606
Drug: lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole 30 mg once daily for 2 weeks
Study: 31409606
Drug: vonoprazan 20
Normalized name: vonoprazan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: vonoprazan 20 mg once daily for 4 weeks
Study: 31409606
Drug: vonoprazan 20
Normalized name: vonoprazan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: vonoprazan 20 mg once daily for 2 weeks (baseline LA grade C/D)
Study: 31409606
Drug: lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole 30 mg once daily for 2 weeks (baseline LA grade C/D)
Study: 31409606
Drug: vonoprazan 20
Normalized name: vonoprazan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: vonoprazan 20 mg once daily for 4 weeks (baseline LA grade C/D)
Study: 31409606
Drug: lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole 30 mg once daily for 4 weeks (baseline LA grade C/D)
Study: 31409606
Drug: vonoprazan 20
Normalized name: vonoprazan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: vonoprazan 20 mg once daily for 8 weeks (baseline LA grade C/D)
Study: 31409606
Drug: lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole 30 mg once daily for 8 weeks (baseline LA grade C/D)
Study: 21429025
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) - i.v. infusion of 3.0 µg/kg per h over 5 min followed by continuous infusion at 0.4 µg/kg per h (n = 30)
Study: 15253399
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg elemental iron daily
Study: 15253399
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg elemental iron weekly
Study: 11226079
Drug: HES 130/0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES 130/0.4 (2430 +/- 310 mL administered until the morning of the first postoperative day)
Study: 11226079
Drug: Gelatin (2830
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin (2830 +/- 350 mL administered until the morning of the first postoperative day)
Study: 2655967
Drug: Antiarrhythmic drugs
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drugs (mexiletine, pirmenol, procainamide, propafenone, quinidine, sotalol)
Study: 26868469
Drug: 5% amlexanox
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% amlexanox (lexanox 5% oral paste)
Study: 25796693
Drug: Longbishu Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longbishu Capsule combined with mesylate doxazosin
Study: 20001867
Drug: Bevacizumab in
Normalized name: bevacizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab in combination with paclitaxel or docetaxel
Study: 10383538
Drug: Inhaled (INH)
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled (INH) 20 mg sodium cromoglycate
Study: 10383538
Drug: Inhaled +
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled + oral charcoal (INHC) 20 mg sodium cromoglycate
Study: 10383538
Drug: Oral (ORAL)
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral (ORAL) 20 mg sodium cromoglycate
Study: 10383538
Drug: Oral +
Normalized name: Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral + oral charcoal (ORALC) 20 mg sodium cromoglycate
Study: 8983611
Drug: Bupivacaine (total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (total of 20 ml, 0.25 per cent) injected into the subcutaneous periportal tissue and periportal parietal peritoneal injection of bupivacaine (total of 20 ml, 0.25 per cent)
Study: 8983611
Drug: Standard technique
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard technique with bupivacaine (total of 20 ml, 0.5 per cent) injected into the subcutaneous periportal tissue
Study: 1840158
Drug: ciclopiroxolamine (cic)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ciclopiroxolamine (cic) cream
Study: 7055343
Drug: Fenoterol (Berotec)
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (Berotec) delivered as inhalation powder
Study: 31126258
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus trastuzumab (T)
Study: 31126258
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus trastuzumab (T) plus pertuzumab (P)
Study: 24038152
Drug: Alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 70 mg QW
Study: 23587455
Drug: Intravenous parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Intravenous parecoxib at a dose of 40 mg followed by 40 mg every 12 h for 48 h (Group P)
Study: 20459801
Drug: Low-dose continuous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose continuous infusion of furosemide, titrated to urine output
Study: 16629791
Drug: Salt chamber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt chamber treatment (active group)
Study: 11185635
Drug: Telmisartan 120
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan 120 mg administered between dialyses
Study: 11185635
Drug: Telmisartan 120
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan 120 mg administered during dialysis
Study: 8866807
Drug: qd SSKI
Approvals — FDA: no, EMA: no, PMDA: no
Description: qd SSKI (one daily dose)
Study: 8866807
Drug: tid SSKI
Approvals — FDA: no, EMA: no, PMDA: no
Description: tid SSKI (three daily doses)
Study: 8499751
Drug: Pseudomonas hyperimmunoglobulin
Normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudomonas hyperimmunoglobulin (Psomaglobin N) 250 mg/kg on days 3, 5, 7, 10, and 13
Study: 8499751
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups with inhalation injury
Study: 31563889
Drug: Multiple passes
Normalized name: MED PASS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple passes or rescue treatment
Study: 30264120
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy with intravenous ertapenem for 3 days followed by 7 days of oral levofloxacin and metronidazole
Study: 25011647
Drug: 10 grams
Normalized name: immunoglobulin G
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 grams of prebiotic (inulin/oligofructose) daily for 12 weeks
Study: 25011647
Drug: 10 grams
Normalized name: immunoglobulin G
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 grams placebo (maltodextrin) daily for 12 weeks
Study: 22138360
Drug: Fermented sea
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented sea tangle (FST) 1.5 g/day for 4 weeks
Study: 17335309
Drug: Medication Events
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Medication Events Monitoring System (MEMS)
Study: 10448449
Drug: Mianserin (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin (15 mg/day)
Study: 9038524
Drug: Mild stimulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild stimulant laxative (Dulcolax)
Study: 9038524
Drug: Osmotic laxative
Normalized name: HYPEROSMOTIC LAXATIVES
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osmotic laxative (Citramag)
Study: 29396845
Drug: Multiple-choice test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-choice test with genotypes LG, VE, J, MG, MOP, HS-20, VA, MT
Study: 27103607
Drug: Biologic therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic therapies targeting immunoglobulin E (IgE) and interleukin (IL)-5 pathways in CRSwNP patients.
Study: 27103607
Drug: Biologic therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic therapies targeting the IL-4/IL-13 pathway and other type 2 inflammatory pathways in CRSwNP patients.
Study: 24292155
Drug: Q-switched Nd:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q-switched Nd:YAG laser plus Er:YAG micropeel (combined therapy)